IceCure Medical (NASDAQ:ICCM) Posts Earnings Results, Beats Expectations By $0.10 EPS

IceCure Medical (NASDAQ:ICCM) released its earnings results on Tuesday. The company reported $0.06 EPS for the quarter, beating the consensus estimate of ($0.04) by $0.10, FiscalAI reports. IceCure Medical had a negative return on equity of 243.68% and a negative net margin of 513.95%.The firm had revenue of $1.28 million during the quarter, compared to analyst estimates of $1.30 million.

IceCure Medical Price Performance

ICCM stock opened at $0.73 on Tuesday. The firm has a market cap of $50.15 million, a PE ratio of -2.81 and a beta of 0.29. IceCure Medical has a 12 month low of $0.54 and a 12 month high of $1.53. The firm has a 50 day simple moving average of $0.63 and a 200 day simple moving average of $0.75.

Institutional Investors Weigh In On IceCure Medical

An institutional investor recently bought a new position in IceCure Medical stock. Virtu Financial LLC acquired a new position in shares of IceCure Medical Ltd. (NASDAQ:ICCM) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 64,524 shares of the company’s stock, valued at approximately $39,000. Virtu Financial LLC owned approximately 0.09% of IceCure Medical as of its most recent SEC filing. 0.62% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ICCM has been the topic of a number of research analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of IceCure Medical in a research note on Thursday, January 22nd. Wall Street Zen raised shares of IceCure Medical from a “sell” rating to a “hold” rating in a research note on Saturday, February 7th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $2.64.

IceCure Medical Company Profile

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.